GENUS ONCOLOGY - THE MUC1-C COMPANY
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target

Targeting the Extracellular Domain

The demonstration that targeting MUC1-C is an effective therapeutic approach for cancer treatment has emphasized the importance of developing other agents that are directed against this oncoprotein.  

Early attempts at targeting MUC1 that focused on the development of MAbs against MUC1-N were unsuccessful largely because this subunit is shed from the cancer cell surface.  Other MAbs have been developed that react with MUC1-N at the junction with MUC1-C.  In contrast to MUC1-N, the MUC1-C subunit is not shed; in this regard and to our knowledge, there are no MAbs that react with the MUC1-C 58-aa extracellular domain, other than the novel clones we have developed that bind selectively to this region. These high affinity antibodies react with the surface of MUC1-C-expressing cancer cells and undergo internalization, a process of importance for the intracellular delivery of therapeutic agents and GO-203/NPs.   

The generation of MAbs against the MUC1-C extracellular domain (MUC1-C/ED) provides an opportunity for developing novel therapeutic approaches that target MUC1-C on the surface of cancer cells.  In this way, there are multiple potential applications for MAbs that bind to cell surface proteins: 
  1. antibody-drug conjugates (ADCs)
  2. antibody-dependent cellular cytotoxicity (ADCC)
  3. complement-mediated cytotoxicity (CMC)
  4. bispecific antibodies
  5. CAR-T or CAR-NK cells
​
​Our work has focused in part on the development of ADCs, based in part on the preliminary findings that these conjugates are effective in killing cancer cells growing in vitro and as xenografts in nude mice. 

Company

About Us
Management
Board of Directors
​Contact
​
Sitemap

Science

MUC1-C
Why Target?
MUC1-C in Stem Cells
Publications

Programs

Targeting
Biomarker
Intellectual Property

Pipeline

Pipeline
​Clinical Trials

News

News
​Publications
© COPYRIGHT 2021 ALL RIGHTS RESERVED.
  • Company
    • Mission
    • About Us
    • Genus Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Clinical and Research Partners
    • Contact
    • Sitemap
  • Why Target MUC1-C?
  • Clinical Trials
    • Summary
    • GO-203
    • Phase 2 AML Clinical Trial
  • The Science
    • Overview
    • MUC1 in Human Cancer: The Numbers
    • MUC1 in Human Cancer: Overexpression
    • Target for Carcinoma Stem-Like Cell
    • Target for Leukemia Stem Cell
    • MUC1-C is an Attractive Target for Reversing Immune Evasion
    • Intellectual Property
  • Programs
    • Pipeline
    • Targeting the Cytoplasmic Domain
    • Targeting the Extracellular Domain
    • Biomarker Program
  • News & Publications
    • News
    • Publications >
      • Complete Listing
      • Role of MUC1-C in Signal Transduction
      • Role of MUC1-C in Epigenetic Regulation
      • Role of MUC1-C in Immune Evasion
      • MUC1 Vaccine
      • MUC1-C in Stem-like Cells
      • MUC1-C inhibitor formulated in Nanoparticles
      • MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
      • MUC1-C is a druggable target